Market Overview

UPDATE: BMO Capital Markets Reiterates Market Perform Rating, Raises PT on Harte-Hanks

Related HHS
Earnings Scheduled For September 28, 2017
Earnings Scheduled For August 16, 2017

In a report published Friday, BMO Capital Markets reiterated its Market Perform rating on Harte-Hanks (NYSE: HHS), and raised its price target from $6.00 to $8.00.

BMO Capital Markets noted, “We believe yesterday's 28% move was driven by guidance for revenue growth at Direct Marketing this year, and to a lesser extent by ‘less bad' results at Shoppers. On the former, the unveiling of the TRUE Health + Wellness agency is intriguing, but Harte-Hanks isn't alone in repositioning to attack the healthcare space (MDCA is also getting aggressive in this area); we're more positive on the more visible revenue opportunity for Trillium software following Obama's reelection and greater certainty around financial regulation, though we prefer to play this trend through SAPE. Furthermore, the continued challenges in the technology vertical give caution, and we don't believe it is entirely related to European macro. On Shoppers, we recognize the brighter outlook post Florida sale and believe direct mail is underappreciated; however unlike Valassis's national platform, Harte-Hanks primarily appeals to smaller local businesses where the weak economy is most acute and free social/digital opportunities are increasingly appealing.”

Harte-Hanks closed on Thursday at $8.19.

Latest Ratings for HHS

Nov 2017Noble FinancialUpgradesHoldBuy
Mar 2016BMO CapitalDowngradesOutperformMarket Perform
Dec 2015Singular ResearchInitiates Coverage onBuy

View More Analyst Ratings for HHS
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Price Target Analyst Ratings


Related Articles (HHS)

View Comments and Join the Discussion!

Partner Center